Müjde Durmaz

4PUBLICATIONS
10CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 12, 2024
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma.

Carolien C H M Maas, David van Klaveren, Müjde Durmaz

|Jan 04, 2024
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.

Elise R A Pennings, Müjde Durmaz, Otto Visser

|Sep 02, 2022
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.

Diana Al-Sarayfi, Frederik O Meeuwes, Müjde Durmaz

|Mar 10, 2022
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.

Müjde Durmaz, Otto Visser, Eduardus F M Posthuma

Pageof 1

Frequent Collaborators

4 joint publications

Martine E D Chamuleau

3 joint publications

Avinash G Dinmohamed

2 joint publications

Marie José Kersten

1 joint publications

Daphne de Jong